High Morphine Dose

Phase 1Small molecule

YYale University

High Morphine Dose is one of 16 small molecule programs targeting Headache. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConcussionActive, not recruiting

ConcussionPhase 1

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Concussion

#DrugCompanyPhaseTrials

Pamelor

SSpecgx

Approved

1 2

Prometrium

Ferring

Approved

1 3

Tasmar

BBausch Health Americas, Inc.

Approved

—4

Lithobid

SSolvay Pharmaceuticals

Approved

—5

Capromorelin

UUniversity of Aarhus

Phase 2

1 6

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 2

1 7

Riboflavin

CCornea and Laser Eye Institute

Phase 2

2 8

Marcaine

IInnocoll

Phase 1

1 9

Neurontin

VViatris Specialty LLC

Phase 1

1 10

Docosahexaenoic Acid

MMicelle BioPharma Inc

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Not yet recruiting

Psilocybin

NCT06992999

Clinical

Trials by Indication[1]

Impairment2 trials

Examine the Feasibility of a Standardized Field Test for Marijuana and Alcohol Impairment: Laboratory Evaluations

Completed·YYale University·Phase 1·NCT04856566·41 enrolled

Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations

Completed·YYale University·Phase 1·NCT03191084·26 enrolled

Concussion1 trial

Effects of Psilocybin in Concussion Headache

Terminated·YYale University·Phase 1·NCT03806985·12 enrolled

Smoking1 trial

IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate

Recruiting·YYale University·Phase 1·NCT05176418·70 enrolled

Impaired Driving1 trial

Neuroscience of Marijuana Impaired Driving

Completed·YYale University·Phase 1·NCT02757313·62 enrolled

Psilocybin1 trial

Psilocybin for Treatment of OCD-2

Not yet recruiting·FFrancisco A Moreno·Phase 1/2·NCT06992999·20 enrolled

3 more indications

Headache1 trial

Psilocybin for the Treatment of Migraine Headache

Completed·YYale University·Phase 1·NCT03341689·14 enrolled

Imaging1 trial

Understanding Factors That Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine Receptors

Withdrawn·YYale University·N/A·NCT04258852

Opioid1 trial

Neuroimmune Effects of Opioid Administration

Completed·YYale University·Phase 1·NCT03801629·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for High Morphine Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — High Morphine Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for High Morphine Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: YYale University

High Morphine Dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Impairment2 trials

Concussion1 trial

Smoking1 trial

Impaired Driving1 trial

Psilocybin1 trial

Headache1 trial

Imaging1 trial

Opioid1 trial

References

Drug Info

Quick Facts

Related News